Key result
Factor XI inhibitors for AF may lower gastrointestinal bleeding risk and enable monthly dosing.
Why the study?
Factor XI inhibitors are undergoing clinical trials for anticoagulation in atrial fibrillation, but none have obtained regulatory approval yet.
Do factor XI inhibitors provide safe and effective anticoagulation with reduced bleeding risk in patients with atrial fibrillation?
Do factor XI inhibitors provide safe and effective anticoagulation with reduced bleeding risk in patients with atrial fibrillation?
Factor XI inhibitors represent a promising emerging class of anticoagulants for atrial fibrillation that may offer reduced bleeding risks and more convenient dosing compared to current therapies.
Atrial fibrillation constitutes a substantial global health issue, with its prevalence expected to increase significantly in the coming years. The effective management of atrial fibrillation, particularly regarding the prevention of ischemic stroke and systemic embolism, has progressed with the introduction of direct oral anticoagulants, which have shown a reduction in bleeding risks when compared to warfarin. The oral factor Xa inhibitors, such as apixaban and rivaroxaban, are considered the first line for anticoagulation in cases of atrial fibrillation. Several factor XI inhibitors, including abelacimab, asundexian, osocimab, gruticibart, milvexian, and fesomersen, are currently undergoing clinical trials for similar therapeutic purposes. However, none of the factor XI inhibitors have obtained regulatory approval yet. This review article aims to emphasize the recent trials evaluating these factor XI inhibitors with a special focus on abelacimab. Abelacimab may signify a promising advancement in anticoagulation therapy, providing potential advantages such as reduced gastrointestinal bleeding risks and the convenience of monthly dosing.
No takes yet. Share an insight, caveat, or question.
Muhammad Adnan Zaman (2025) conducted a review in Atrial fibrillation. Factor XI inhibitors (abelacimab) was evaluated. Factor XI inhibitors, particularly abelacimab, are under investigation for atrial fibrillation and may offer advantages such as reduced gastrointestinal bleeding risks and monthly dosing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: